Clinical trials: TACE
Hepatocellular Carcinoma (HCC), Real World Study
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of hepatocellular carcinoma and has gradually become the cornerstone of advanced liver cancer treatment.
- Trial name
- NCT07078292
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Enhanced Recovery After Surgery, Multimodal Analgesia
Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma
To evaluate the effectiveness of the combination of hydrochloride hydromorphone and flurbiprofen ester for post-TACE intravenous patient-controlled intravenous analgesia (PCIA).
- Conditions
- Enhanced Recovery After Surgery, Multimodal Analgesia, Real-world Study, Transarterial Chemoembolization
- Trial name
- NCT07315022
- Testing
- hydrochloride hydromorphone + flurbiprofen axetil, conventional analgesia
- Where
- China
- Volunteers
- 129 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization…
- Trial name
- NCT06904196
- Testing
- Lenvatinib plus SIRT, Lenvatinib
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
- Trial name
- NCT04974281
- Testing
- PD-1 and Lenvatinib Plus TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Liver Cancer
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
- Trial name
- NCT01042041
- Testing
- sorafenib tosylate, doxorubicin hydrochloride, cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization)
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment…
- Conditions
- HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT
- Trial name
- NCT07351669
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer Metastatic, Liver Metastases
Irinotecan Drug-eluting Bead Liver Embolisation Registry
Purpose: The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery…
- Trial name
- DLivERDEBIRI (NCT03697044)
- Testing
- Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- The Christie NHS Foundation Trust
HCC
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma
Although the combination of transarterial chemoembolization (TACE) with PD-1 inhibitor plus lenvatinib has become a new standard, the therapeutic efficacy for unresectable hepatocellular carcinoma (uHCC) still requires…
- Trial name
- NCT07340502
- Testing
- TACE, HAIC, PD-1inhibitors
- Volunteers
- 364 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC)
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC).
- Trial name
- NCT07019844
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma
Using Machine Learning to Identify Responders to TACE or HAIC for uHCC
The goal of this observational study is to learn about the efficacy of Transarterial Chemoembolization (TACE) versus Hepatic Arterial Infusion Chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT07368530
- Testing
- Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Diffuse Large B-Cell Lymphoma, Relapsed and Refractory
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based…
- Conditions
- Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization
- Trial name
- NCT07198230
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ting YANG
Hepatocellular Carcinoma
A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)
The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance…
- Trial name
- NCT03086564
- Testing
- ADCC & TACE, TACE
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Yuehua Huang
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
- Trial name
- NCT04997850
- Testing
- lenvatinib + sindilimab/carrelizumab, TACE
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinrui Zhu，MD
Hepatocellular Carcinoma
A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma
Presently,the diagnostic method of small hepatocellular carcinoma has been greatly elevated in China.The treatment is being from simplification to diversification,from entirety to individualization.Confronting small…
- Trial name
- NCT00825474
- Testing
- operation;TACE plus PEI
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HCC, Quality of Life
Multidisciplinary Management of HCC in Elderly Patients
Aim of this study is to evaluate whether treating HCC recurrences in resected elderly patients is advantageous or not.
- Trial name
- NCT03875417
- Testing
- liver resection, Thermic ablation, Transcatheter arterial chemoembolization
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Policlinico Umberto I
Liver Cancer
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01011010
- Testing
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
TACE as an Adjuvant Therapy After Hepatectomy for HCC
Investigators hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival of…
- Trial name
- NCT01966133
- Testing
- Ethiodized Oil + Doxorubicin
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Jia Fan
Hepatocellular Carcinoma
Survival Analysis: TACE vs. Combination Therapy in HCC
This retrospective observational study aimed to assess potential improvements associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC.
- Trial name
- NCT06261138
- Testing
- Transarterial chemoembolization, Systemic treatment
- Where
- China
- Volunteers
- 279 people
- Sponsor
- Zhejiang University